These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 18176149)

  • 41. Affinity maturation of a humanized rat antibody for anti-RAGE therapy: comprehensive mutagenesis reveals a high level of mutational plasticity both inside and outside the complementarity-determining regions.
    Finlay WJ; Cunningham O; Lambert MA; Darmanin-Sheehan A; Liu X; Fennell BJ; Mahon CM; Cummins E; Wade JM; O'Sullivan CM; Tan XY; Piche N; Pittman DD; Paulsen J; Tchistiakova L; Kodangattil S; Gill D; Hufton SE
    J Mol Biol; 2009 May; 388(3):541-58. PubMed ID: 19285987
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Role of Fcgamma receptors in immune regulation and diseases].
    Takai T
    Nihon Rinsho Meneki Gakkai Kaishi; 2005 Oct; 28(5):318-26. PubMed ID: 16276045
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
    Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
    Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lower antibody response to Porphyromonas gingivalis associated with immunoglobulin G Fcgamma receptor IIB polymorphism.
    Honma Y; Sugita N; Kobayashi T; Abiko Y; Yoshie H
    J Periodontal Res; 2008 Dec; 43(6):706-11. PubMed ID: 18705654
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clonal CD27+ CD19+ B cell expansion through inhibition of FC gammaIIR in HCV(+) cryoglobulinemic patients.
    De Re V; Pavan A; Sansonno S; Sansonno D; Racanelli V
    Ann N Y Acad Sci; 2009 Sep; 1173():326-33. PubMed ID: 19758169
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcgammaRIIIb and MHC class II expression on the phagocytotic neutrophils.
    Shibata-Koyama M; Iida S; Misaka H; Mori K; Yano K; Shitara K; Satoh M
    Exp Hematol; 2009 Mar; 37(3):309-21. PubMed ID: 19218011
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions.
    Vega MI; Huerta-Yepez S; Martinez-Paniagua M; Martinez-Miguel B; Hernandez-Pando R; González-Bonilla CR; Chinn P; Hanna N; Hariharan K; Jazirehi AR; Bonavida B
    Clin Cancer Res; 2009 Nov; 15(21):6582-94. PubMed ID: 19861448
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intravenous IgG: biological modulating molecules.
    Luzi G; Bongiorno F; Paparo Barbaro S; Bruno G
    J Biol Regul Homeost Agents; 2009; 23(1):1-9. PubMed ID: 19321040
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A close look at human IgG sialylation and subclass distribution after lectin fractionation.
    Stadlmann J; Weber A; Pabst M; Anderle H; Kunert R; Ehrlich HJ; Peter Schwarz H; Altmann F
    Proteomics; 2009 Sep; 9(17):4143-53. PubMed ID: 19688751
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators.
    Dimasi N; Gao C; Fleming R; Woods RM; Yao XT; Shirinian L; Kiener PA; Wu H
    J Mol Biol; 2009 Oct; 393(3):672-92. PubMed ID: 19699208
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fcγ receptors: genetic variation, function, and disease.
    Hargreaves CE; Rose-Zerilli MJ; Machado LR; Iriyama C; Hollox EJ; Cragg MS; Strefford JC
    Immunol Rev; 2015 Nov; 268(1):6-24. PubMed ID: 26497510
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ligand binding but undetected functional response of FcR after their capture by T cells via trogocytosis.
    Hudrisier D; Clemenceau B; Balor S; Daubeuf S; Magdeleine E; Daëron M; Bruhns P; Vié H
    J Immunol; 2009 Nov; 183(10):6102-13. PubMed ID: 19841164
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Generation of canine-human Fc IgE chimeric antibodies for the determination of the canine IgE domain of interaction with Fc epsilon RI alpha.
    Hunter MJ; Vratimos AP; Housden JE; Helm BA
    Mol Immunol; 2008 Apr; 45(8):2262-8. PubMed ID: 18187193
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Surface display of IgG Fc on baculovirus vectors enhances binding to antigen-presenting cells and cell lines expressing Fc receptors.
    Martyn JC; Cardin AJ; Wines BD; Cendron A; Li S; Mackenzie J; Powell M; Gowans EJ
    Arch Virol; 2009; 154(7):1129-38. PubMed ID: 19557497
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Structure and function of immunoglobulins.
    Schroeder HW; Cavacini L
    J Allergy Clin Immunol; 2010 Feb; 125(2 Suppl 2):S41-52. PubMed ID: 20176268
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Structure and function of autoantibodies and their role in autoimmune rheumatic diseases.
    Rahman A; Giles IP
    Expert Rev Clin Immunol; 2006 Mar; 2(2):225-36. PubMed ID: 20477073
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of Fc receptors and complement in autoimmunity.
    Baumann U; Schmidt RE
    Adv Exp Med Biol; 2001; 495():219-25. PubMed ID: 11774570
    [No Abstract]   [Full Text] [Related]  

  • 58. The IgA receptor complex: a two-for-one deal.
    Wurzburg BA; Jardetzky TS
    Nat Struct Biol; 2003 Aug; 10(8):585-7. PubMed ID: 12886289
    [No Abstract]   [Full Text] [Related]  

  • 59. [Immune dysfunctions in Fc receptor-deficient mice].
    Takai T
    Tanpakushitsu Kakusan Koso; 2002 Dec; 47(16 Suppl):2375-81. PubMed ID: 12518464
    [No Abstract]   [Full Text] [Related]  

  • 60. Activating and inhibitory FcgammaRs in autoimmune disorders.
    Nimmerjahn F
    Springer Semin Immunopathol; 2006 Dec; 28(4):305-19. PubMed ID: 17115158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.